Urogen Pharma (NASDAQ:URGN) issued its quarterly earnings data on Thursday, March 15th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.09), Morningstar.com reports. The business had revenue of $0.33 million during the quarter.
URGN opened at $59.08 on Friday. Urogen Pharma has a one year low of $13.01 and a one year high of $65.89. The firm has a market capitalization of $869.50 and a PE ratio of -27.61.
A number of research analysts recently issued reports on the company. UBS upgraded Urogen Pharma from a “market perform” rating to an “outperform” rating in a research report on Wednesday. Oppenheimer restated a “buy” rating on shares of Urogen Pharma in a research report on Thursday, March 22nd. Jefferies Group restated a “buy” rating on shares of Urogen Pharma in a research report on Monday, March 19th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $65.00 target price on shares of Urogen Pharma in a research note on Friday, March 16th. Finally, Raymond James Financial raised Urogen Pharma from a “market perform” rating to an “outperform” rating in a research note on Wednesday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $45.50.
Institutional investors and hedge funds have recently bought and sold shares of the company. DSAM Partners London Ltd raised its stake in shares of Urogen Pharma by 83.2% in the 4th quarter. DSAM Partners London Ltd now owns 136,500 shares of the company’s stock worth $5,079,000 after buying an additional 62,000 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of Urogen Pharma in the 3rd quarter worth $293,000. Lyon Street Capital LLC bought a new stake in shares of Urogen Pharma in the 3rd quarter worth $1,316,000. Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of Urogen Pharma in the 4th quarter worth $166,000. Finally, Spark Investment Management LLC raised its stake in shares of Urogen Pharma by 90.6% in the 4th quarter. Spark Investment Management LLC now owns 70,700 shares of the company’s stock worth $2,630,000 after buying an additional 33,600 shares in the last quarter. 50.49% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Urogen Pharma (URGN) Releases Earnings Results, Misses Estimates By $0.09 EPS” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/urogen-pharma-urgn-releases-quarterly-earnings-results-misses-expectations-by-0-09-eps.html.
Urogen Pharma Company Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.